In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming ...
Feb 10, 2021
0
64
A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to ...
Jan 15, 2021
0
5
In a study in mice and human cells, Johns Hopkins Medicine researchers say that they have developed a tiny, yet effective method for preventing premature birth. The vaginally-delivered treatment contains nanosized (billionth ...
Jan 13, 2021
0
35
The combination of ibrutinib plus rituximab is approved for the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL). In an early benefit assessment, the German Institute for Quality and Efficiency ...
Jan 5, 2021
0
5
Researchers have identified acute myeloid leukemia as a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard ...
Oct 14, 2020
0
9
Breast cancer is the most frequent neoplasm among women, impacting 2.1 million women per year. It also has a high risk for intracranial spread. Researchers estimate that up to 30% of all patients with cancer will eventually ...
Sep 28, 2020
0
0
Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop—and, in many cases, resistant to lifesaving drugs. Now scientists at The University of ...
Sep 22, 2020
0
30
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.
Sep 19, 2020
0
7
Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows.
Sep 15, 2020
0
8
A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence (NICE).
Sep 7, 2020
0
3
